DGAP-Adhoc

HeidelbergCement AG: HeidelbergCement publishes preliminary business figures for 2021 - Revenue and earnings growth above guidance and market expectations

DGAP-Ad-hoc: HeidelbergCement AG / Key word(s): Development of Sales/Annual Results HeidelbergCement AG: HeidelbergCement publishes preliminary business figures for 2021 - Revenue and earnings growth above guidance and market expectations 31-Jan-2022 / 18:11 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. In the course of the preparation of the consolidated financial statements of HeidelbergCement AG for the financial year 2021, the revenue and results of the HeidelbergCement Group are in part significantly above the published forecast of the company and the current capital market expectations. The capital market expectations are based on the mean value of the latest consensus estimates of financial analysts, compiled by Vara Research on January 28, 2022.

Therefore, HeidelbergCement AG publishes already today the following preliminary key figures from the consolidated financial statements for the financial year 2021 and the fourth quarter of 2021, respectively:

- Preliminary revenue in the financial year 2021 is expected to be approximately EUR 18.7 billion (previous year: 17.6). This represents an increase of around 8% year-on-year on a like-for-like basis (before exchange rate and consolidation effects). The company expected a slight increase in revenue before exchange rate and consolidation effects in 2021.

- Preliminary revenue in the fourth quarter of 2021 is expected to be approximately EUR 4.7 (previous year: 4.5) billion. This corresponds to an increase of around 7% compared with the prior-year quarter on a like-for-like basis.

- Preliminary result from current operations before depreciation and amortization (RCOBD) in the financial year 2021 is expected to be EUR 3,875 million (previous year: 3,707). This corresponds to an increase of around 6% year-on-year on a like-for-like basis. The company expected a strong increase in RCOBD in 2021. The capital market expects EUR 3,826 million for this key figure.